| Dec 11 |
Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ...
|
| Dec 9 |
Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts
|
| Dec 8 |
Citi bullish on Biomea amid selloff, says market misinterpreting drug data
|
| Dec 8 |
Biomea stock tumbles in wake of Phase 2 data for diabetes drug
|
| Dec 8 |
Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin Res...
|
| Dec 7 |
Biomea Fusion spikes after mid-stage data for diabetes candidate
|
| Dec 7 |
Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular ...
|
| Dec 5 |
Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes
|
| Nov 29 |
Why Patterson Companies Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
|
| Nov 29 |
Why Workday Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
|
